May. 18 at 9:36 PM
$SNSE Short squeeze probability estimate 65–75%
~855K shares short against only ~1.34M shares outstanding — 63–91% of float depending on source
19.3 days to cover at current volume means shorts are deeply trapped; any buying surge could trigger a cascade
Short interest up +334% over 12 months — shorts have been pressing aggressively on what is a tiny float
Stock already up +253% in a year and near 52-week highs
Hard catalyst: PIKTOR Phase 2 topline data due ~September 2026 in
$200M private placement behind the company — funded and operational
Key risks: Volume is very thin (~16–44K shares/day) — the double-edged sword of a micro-float is that it can gap violently in either direction. An S-3 shelf registration was filed April 29, 2026, flagging potential future dilution. Clinical data could disappoint. No revenue, negative operating cash flow. This is a high-conviction squeeze target but with binary clinical risk baked in. Position sizing and stop discipline are critical. *Claude dashboard.
